| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development expenses | 679 | 1,566* | ||
| General and administrative expenses | 1,279 | 389* | ||
| Total operating expenses | 1,958 | 1,955 | ||
| Operating loss | -1,958 | -1,955* | ||
| Other expense direct listing offering costs | 586 | 291* | ||
| Net loss and comprehensive loss | -2,544 | -2,246 | ||
| Basic EPS | -0.05 | -0.049 | ||
| Diluted EPS | -0.05 | -0.049 | ||
| Basic Average Shares | 47,219,329 | 45,422,581 | ||
| Diluted Average Shares | 47,219,329 | 45,422,581 | ||
Polaryx Therapeutics, Inc. (PLYX)
Polaryx Therapeutics, Inc. (PLYX)